Hematologic Malignancies

Sagar Lonial MD Jeff P. Sharman MD Julie M. Vose MD MBA and Farhad Ravandi-Kashani MD review data from key hematologic malignancy presentations from the 2015 clinical oncology meeting in Chicago. Topics include multiple myeloma indolent non-Hodgkin’s Lymphoma chronic lymphocytic leukemia acute leukemia and myelodysplasias.

Share

Program Content

Activities

  • LSC Phenotypes and Outcomes
    Leukemia Stem Cell Phenotypes Correlate With Cytogenetic Risk Factors and Clinical Outcomes
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • MDS and <i>KIR</i> Genes
    KIR Genes Associated With MDS Risk
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • Gilteritinib in R/R AML
    FLT3/Axl Inhibitor Gilteritinib (ASP2215) Safe and Active in Relapsed or Refractory AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • Idelalisib + Ofatumumab in CLL
    Improved PFS With Addition of Idelalisib to Ofatumumab in Previously Treated CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • CR30 as PFS Surrogate in FL
    CR Rate at 30 Mos Is a Feasible Surrogate Endpoint for PFS in First-line Follicular Lymphoma Trials
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • BV+ R-CHOP in DLBCL
    Frontline Brentuximab Vedotin + R-CHOP Yields High Response Rate in DLBCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • Elo + Len/Dex in R/R MM
    ELOQUENT-2: Addition of Elotuzumab to Len/Dex Extends PFS in Relapsed/Refractory Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • ENDEAVOR: Kd vs Vd in Relapsed MM
    ENDEAVOR: Kd Superior to Vd in Relapsed Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • KRd + ASCT in NDMM
    Extended Carfilzomib, Lenalidomide, Dexamethasone + ASCT Effective in Newly Diagnosed MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • Panobinostat/Carfilzomib in MM
    Panobinostat/Carfilzomib With Promising Activity in R/R Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • CTL019 CAR T-cells in NHL
    CD19 CAR-T Cells Induce Durable Responses in Relapsed/Refractory CD19-Positive Lymphomas
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • Outcomes w R-Chemo in FL
    Poorer Outcomes With Rituximab + Chemo in Heavier Patients, Older Men With Follicular Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • GADOLIN Trial in iNHL
    GADOLIN: Obinutuzumab + Bendamustine and Maintenance Obinutuzumab in Rituximab-Refractory Indolent NHL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • Daratumumab in R/R MM
    SIRIUS: Daratumumab Active, Safe in Double Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • HELIOS: Ibrutinib + BR in R/R CLL/SLL
    HELIOS: Longer PFS With Addition of Ibrutinib to Bendamustine/Rituximab in Previously Treated CLL/SLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • Pacritinib in Myelofibrosis
    PERSIST-1: Pacritinib Improved Spleen Volume Reductions in Myelofibrosis vs Best Available Therapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • Downloadable Slideset
    Key Studies in Hematologic Malignancies
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 25, 2015

    Expires: August 23, 2016

  • 19-28ζ CAR T-cells in R/R ALL
    19-28ζ CAR T-Cells Induce High CR Rate in Relapsed/Refractory Adult ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation